FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Inc., a biopharmaceutical company, participated in the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum, where they presented positive results from the first-in-human Phase-1 study of Lucid-21-302 (Lucid-MS), a proposed treatment for multiple sclerosis (MS). The Phase-1 clinical study aimed to evaluate the safety, tolerability, and pharmacokinetics of Lucid-21-302 in healthy volunteers, demonstrating promising results. According to the findings, Lucid-21-302 was well-tolerated within the dose range of 50-300 mg with no serious adverse events reported, showcasing a promising profile for further development.

Lucid-21-302, a non-immunomodulatory, neuroprotective compound, has a unique mechanism aiming to prevent demyelination associated with MS and other neurodegenerative diseases. Preclinical models have shown its potential in preventing demyelination and protecting myelin sheaths. Dr. Andrzej Chruscinski, FSD Pharma’s Vice President for Scientific and Clinical Affairs, expressed optimism regarding the clinical development of Lucid-21-302, highlighting its potential to advance treatments for MS.

The announcement comes as a positive development for FSD Pharma, reflecting its ongoing commitment to addressing neurodegenerative and metabolic disorders. The presentation at ACTRIMS, the largest MS research conference in North America, underscores the significance of the company's research in a global context.